Multiple Doses and Regimens of Cabozantinib in Subjects With Grade IV Astrocytic Tumors in First or Second Relapse

Exclusion Criteria

• •The subject has received certain prior anticancer therapies within a certain amount of time before starting study treatment
• •The subject is receiving warfarin (or other coumarin derivatives) and is unable to switch to low molecular weight heparin
• •The subject has evidence of acute intracranial or intratumoral hemorrhage either by MRI or CT scan. Subjects with resolving hemorrhage changes, punctate hemorrhage, or hemosiderin are eligible
• •The subject is unable to undergo MRI scan (eg, has pacemaker)
• •The subject has received enzyme-inducing anti-epileptic agents within a certain time prior to starting study treatment (eg, carbamazepine, phenytoin, phenobarbital, primidone)
• •The subject has not recovered to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v3.0 Grade ≤ 1 from AEs (except alopecia and lymphopenia) due to surgery, or other medications that were administered prior to study start
• •The subject has evidence of unhealed wounds
• •The subject is pregnant or breast-feeding
• •The subject has serious intercurrent illness or a recent history of serious disease
• •The subject has inherited bleeding diathesis or coagulopathy (disease affecting how blood clots) with the risk of bleeding
• •The subject has a history of any medical or surgical conditions (eg, stomach or intestinal surgery or resection) that would potentially interfere with or alter gastrointestinal function
• •The subject has a history of idiopathic pulmonary fibrosis or interstitial lung disease
• •The subject has received any live virus vaccine or any inactivated vaccine within a certain amount of time before starting study treatment